Keros Therapeutics Ownership | Who Owns Keros Therapeutics?

Overview Forecast RevenueFinancials Chart

Keros Therapeutics Ownership Summary

Keros Therapeutics is owned by 26.50% institutional investors, 3.63% insiders, and 69.87% retail investors. Adar1 capital management is the largest institutional shareholder, holding 13.27% of KROS shares. iShares Russell 2000 ETF is the top mutual fund, with 3.48% of its assets in Keros Therapeutics shares.

KROS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Keros Therapeutics	26.50%	3.63%	69.87%
Sector	Healthcare Stocks	232.86%	10.65%	-143.51%
Industry	Biotech Stocks	382.13%	10.41%	-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Adar1 capital management	5.39M	13.27%	$85.26M
Blackrock	2.51M	8.53%	$114.86M
Madison avenue partners, lp	2.71M	6.67%	$42.84M
Blackrock funding, inc. /de	2.29M	5.64%	$46.64M
Vanguard group	1.53M	3.75%	$31.06M
Tang capital management	1.42M	3.49%	$22.45M
State street	1.30M	3.21%	$20.61M
Orbimed advisors	1.02M	2.51%	$16.12M
Millennium management	878.16K	2.43%	$13.90M
Alkeon capital management	850.51K	2.09%	$13.46M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Adar1 capital management	5.39M	8.01%	$85.26M
Rangeley capital	258.62K	3.54%	$4.09M
Madison avenue partners, lp	2.71M	2.56%	$42.84M
Superstring capital management lp	95.08K	1.48%	$1.50M
Logos global management lp	850.00K	1.21%	$13.45M
Monimus capital management, lp	108.05K	1.05%	$1.71M
Tang capital management	1.42M	0.86%	$22.45M
Redmile group	552.51K	0.85%	$8.74M
Orbimed advisors	1.02M	0.38%	$16.12M
Pdt partners	332.81K	0.33%	$5.27M

Top Buyers

Holder	Shares	% Assets	Change
Renaissance	591.69K	0.02%	436.99K
Blackrock	2.51M	0.00%	347.23K
Millennium management	878.16K	0.01%	305.17K
Qube research	303.12K	0.01%	264.44K
Dimensional fund advisors lp	321.36K	0.00%	263.35K

Top Sellers

Holder	Shares	% Assets	Change
Western standard	-	-	-2.19M
Braidwell lp	-	-	-1.89M
Darwin global management	-	-	-1.69M
Holocene advisors, lp	-	-	-1.20M
Vanguard group	1.53M	0.00%	-1.19M

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	127.30K	0.00%	127.30K	$1.41M
Superstring capital management lp	95.08K	1.48%	95.08K	$1.50M
Norges bank	64.90K	0.00%	64.90K	$1.03M
Empowered funds	60.08K	0.01%	60.08K	$1.22M
Principal financial group	59.59K	0.00%	59.59K	$657.92K

Sold Out

Holder	Change
Clearstead advisors	-3.00
Nelson, van denburg & campbell wealth management group	-4.00
Riggs asset managment	-5.00
Point72 asset management	-6.00
J.safra asset management	-8.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	102	-36.65%	10,764,752	-69.51%	26	0.35%	46	-45.88%	41	2.50%
Sep 30, 2025	153	12.50%	34,356,950	4.91%	84	1.30%	80	1.27%	39	18.18%
Jun 30, 2025	143	-13.86%	35,921,666	4.01%	88	1.22%	82	-14.58%	35	-7.89%
Mar 31, 2025	169	-2.87%	36,741,515	-0.02%	90	0.87%	98	-14.04%	38	22.58%
Dec 31, 2024	168	-1.75%	35,057,503	0.30%	97	1.04%	110	14.58%	30	-34.78%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Russell 2000 ETF	688.78K	3.48%	5.83K
Vanguard Total Stock Mkt Idx Inv	595.32K	3.02%	-
State Street® SPDR® S&P® Biotech ETF	504.06K	2.56%	2.80K
Vanguard US Total Market Shares ETF	960.39K	2.37%	1.20K
Fidelity Select Health Care	820.00K	2.02%	20.00K
Federated Hermes MDT SCC Institutional	382.34K	1.93%	17.90K
Federated Hermes MDT Small Cap Core IS	382.34K	1.93%	17.90K
SPDR® S&P Biotech ETF	661.47K	1.63%	1.48K
Fidelity Small Cap Index	286.13K	1.45%	3.18K
ACAP Strategic A	419.59K	1.38%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 15, 2026	BIENAIME JEAN JACQUES	-	Buy	$11.70K
Mar 09, 2026	BIENAIME JEAN JACQUES	-	Buy	$22.42K
Feb 19, 2026	Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Sell	$113.43K
Feb 18, 2026	Lerner Lorena Raquel	Chief Science Officer	Sell	$63.32K
Feb 18, 2026	Cho Esther	SVP, General Counsel	Sell	$77.58K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	1	-
2026 Q1	1	4
2025 Q4	-	2
2025 Q3	-	-
2025 Q2	5	-

KROS Ownership FAQ

Who Owns Keros Therapeutics?

Keros Therapeutics shareholders are primarily institutional investors at 26.50%, followed by 3.63% insiders and 69.87% retail investors. The average institutional ownership in Keros Therapeutics's industry, Biotech Stocks , is 382.13%, which Keros Therapeutics falls below.

Who owns the most shares of Keros Therapeutics?

Keros Therapeutics’s largest shareholders are Adar1 capital management (5.39M shares, 13.27%), Blackrock (2.51M shares, 8.53%), and Madison avenue partners, lp (2.71M shares, 6.67%). Together, they hold 28.47% of Keros Therapeutics’s total shares outstanding.

Does Blackrock own Keros Therapeutics?

Yes, BlackRock owns 8.53% of Keros Therapeutics, totaling 2.51M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 114.86M$. In the last quarter, BlackRock increased its holdings by 347.23K shares, a 16.03% change.

Who is Keros Therapeutics’s biggest shareholder by percentage of total assets invested?

Adar1 capital management is Keros Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.01% of its assets in 5.39M Keros Therapeutics shares, valued at 85.26M$.

Who is the top mutual fund holder of Keros Therapeutics shares?

iShares Russell 2000 ETF is the top mutual fund holder of Keros Therapeutics shares, with 3.48% of its total shares outstanding invested in 688.78K Keros Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools